It is well established that chronic autonomic sympathetic/ parasympathetic imbalance plays a crucial role in the development of heart failure (HF) (1) (2) (3) (4) ). There appears to be a significant increase in adrenergic signaling in HF, even in the initial stages of cardiac remodeling before the onset of heart dysfunction (5). The hyperadrenergic state contributes to cardiac remodeling (5, 6) , and this correlates with higher morbidity and mortality (7) .
Early changes in autonomic control in HF also involve decreased parasympathetic regulation (8) (9) (10) . Altered heart rate (HR) regulation due to changes in vagal nerve activity has been observed shortly after induction of left ventricular (LV) dysfunction (11) . However, how compensatory changes in cholinergic signaling could contribute to development of HF is still not fully understood.
Previous experiments have suggested that compensatory transdifferentiation of sympathetic neurons to a cholinergic phenotype during HF can help offset mortality, suggesting a protective role for this compensatory mechanism (12) . In an animal model of HF, concomitant treatment using vagal nerve stimulation and b-blockade therapy has been shown to improve cardiac contractility and animal survival (13, 14) . Furthermore, both cardiac remodeling and mortality were reduced in animal models of HF after chronic treatment with the cholinesterase inhibitor donepezil (15, 16) . Finally, increasing extracellular ACh levels through administration of a peripheral quaternary cholinesterase inhibitor, pyridostigmine, led to greater vagal control of the heart and reduced ventricular dysfunction in rats with HF (17, 18) .
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an improvement in New York Heart Association class score as well as LV end-systolic volume, which refers to the residual blood in the heart after contraction (19) . Moreover, epidemiologic observation revealed that patients with Alzheimer disease receiving cholinesterase inhibitors present decreased risk of myocardial infarction and cardiovascular death compared with patients who did not receive or who received lower doses of cholinesterase inhibitors (20) . Distinct ways to genetically disturb cholinergic activity in mice suggest that intact cholinergic signaling is critical for heart health and ventricular function (21) (22) (23) (24) , despite the sparse levels of cholinergic innervation outside the atria (25) . Regulated autocrine/paracrine secretion of nonneuronal ACh by cardiomyocytes has recently emerged as a new mechanism by which heart cells can regulate and increase parasympathetic signaling (26) . In support of this mechanism, cardiomyocyte overexpression of choline acetyltransferase (ChAT) and ACh in transgenic mice protects against myocardial infarction (24) . In addition, cardiomyocyte-selective elimination of the vesicular acetylcholine transporter (VAChT), a protein responsible for packing ACh in secretory vesicles, led to altered cardiovascular regulation during exercise and induced earlystage cardiac remodeling and cardiomyocyte stress (21) .
Here we found that both healthy and diseased human cardiomyocytes express bona fide presynaptic markers of the cholinergic system, namely ChAT and VAChT. Furthermore, LV tissue from human patients with nonischemic dilated cardiomyopathy (NICM) displayed a significant increase in the expression of VAChT, including VAChT present in cardiomyocytes, compared with age-matched controls.
In order to further examine the importance of the nonneuronal cholinergic system (NNCS) in cardiac disease, we used genetically modified mice in which either VAChT or ChAT was selectively deleted from cardiomyocytes or in which VAChT was overexpressed. The mice were chronically treated with angiotensin II (Ang II) to induce limited cardiac remodeling resulting from chronic vasoconstriction as well as direct effects of Ang II on ventricular cardiomyocytes. This approach allowed us to determine the role of the cholinergic system in the early stages of cardiac disease, before the onset of HF. Our animal data suggest that compensatory changes in VAChT levels in humans may play a role in mitigating the extent of cardiac remodeling in HF.
MATERIALS AND METHODS

Human tissue samples
LV tissue samples were obtained from the Duke Human Heart Repository (Durham, NC, USA). LV myocardium was obtained from 7 HF patients with NICM and age-matched nonfailing individuals. LV tissue was flash frozen for RNA and protein extraction and embedded in optimal cutting temperature compound for immunostaining. The use of these samples was approved by the institutional review board at Duke University Medical Center (Durham, NC, USA).
Animal models
Only male mice aged 3 to 6 mo were used for all in vivo experiments. Cardiomyocyte-specific VAChT-or ChAT-knockout (KO) [cVAChT (VAChT Myh6-Cre-VAChT-flox/flox ) or cChAT (ChAT Myh6-Cre-ChAT-flox/flox )] mice were generated as described in a previous study (21) . cVAChT mice were back-crossed to the C57BL/6J background for at least 6 generations, and cChAT mice were back-crossed to the C57BL/6J background for least 10 generations. Myh6-Cre+ (B6.FVB-Tg(Myh6-cre)2182Mds/J) mice were back-crossed to the C57Bl/6j background for at least 10 generations. ChAT-ChR2-EYFP mice overexpressing the VAChT (B6.Cg-Tg (Chat-COP4*H134R/EYFP,Slc18a3)6Gfng/J) (27) (28) (29) were kindly donated by G. Feng (Massachusetts Institute of Technology, Boston, MA, USA) in 2012 and back-crossed to the C57BL/6J background for at least 6 generations (27, 29) .
Ang II infusion to induce cardiac remodeling
Ang II (A9525; Sigma-Aldrich, St. Louis, MO, USA) was dissolved in sterile saline and added to osmotic pumps (model 1002; Alzet, New York, NY, USA) to deliver a dose of 3 mg/kg/d. The pumps were implanted subcutaneously, and Ang II or saline was infused for 2 wk. Mice were then housed for an additional 2 wk to allow remodeling before experimental use.
Echocardiography M-mode echocardiography was performed after Ang II or saline treatments. LV and right ventricular ejection fraction and fractional shortening were measured with the Vevo 2100 ultrasound imaging system (VisualSonics, Toronto, ON, Canada). Briefly, 2-dimensional images of the heart were obtained in short-axis view using a dynamically focused 40 MHz probe. The M-mode cursor was positioned perpendicular to the LV anterior and posterior walls. The LV internal end-diastolic dimension (LVIDd) and LV internal systolic dimension (LVID) were measured from M-mode recordings. LV ejection fraction was calculated as:
]/(LVIDd) 3 3 100. Fractional shortening was calculated as: FS (%) = (LVIDd 2 LVIDs)/LVIDd 3 100. The M-mode measurements of the LV ejection fraction and fractional shortening were averaged from 3 cycles.
Reactive oxygen species measurement
Reactive oxygen species levels were measured using the MitoSOX Red superoxide indicator (Invitrogen, Carlsbad, CA, USA) as previously described (22) .
Protein oxidation levels
Hearts from saline-or Ang II-treated mice were isolated, fixed, and embedded in paraffin. Tissue sections (5 mm) were obtained, and oxidized protein levels were analyzed using the OxyIHC Oxidative Stress Kit (EMD Millipore, Billerica, MA, USA) following the manufacturer's directions. Briefly, carbonyl groups on oxidized proteins are derivatized with 2,4-dinitrophenylhydrazine and the DNP-derivatized proteins detected using an antibody specific to the DNP moiety. This was followed by a standard immunohistochemistry procedure to stain oxidized proteins. The intensity of the staining was measured by ImageJ software (Image Processing and Analysis in Java; U.S. National Institutes of Health, Bethesda, MD, USA) to quantify the extent of protein oxidation.
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Histologic analysis
Sections (5 mm) were obtained from saline-and Ang II-treated mice. The tissue sections were stained with hematoxylin and eosin using standard procedures. Light microscopic images were acquired at 203 magnification at distinct locations within the LV free wall.
Cardiomyocyte cell surface area was measured using hematoxylin and eosin-stained sections where cardiomyocyte edges were distinctly observable. Cell surface was measured in sections obtained from at least 4 mice per genotype.
Cardiac fibrosis
Sections (5 mm) obtained after Ang II or saline treatment were stained with Trichrome C using standard procedures to analyze extent of cardiac fibrosis. Light microscopic images were acquired at 320 magnification at separate locations within the LV wall to analyze both interstitial and perivascular collagen deposition.
Quantitative polymerase chain reaction/reverse transcription-polymerase chain reaction Total RNA from flash frozen whole hearts or ventricular tissue was extracted using the Bio-Rad Aurum Total Fatty and Fibrous Tissue kit according to the manufacturer's protocol (Bio-Rad, Hercules, CA, USA). A total of 500 ng of total RNA was used to synthesize 20 ml of cDNA using the Applied Biosystems High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). The synthesized cDNA was diluted by half. The total reaction volume for quantitative polymerase chain reaction (qPCR) was as follows: 1 ml diluted cDNA, 2.5 ml SYBR Green, 0.5 ml each of the forward and reverse primers, and 0.5 ml of Milli-Q H 2 O. Primers for VAChT, ChAT, acetylcholinesterase (AChE), b-myosin heavy chain, and atrial natriuretic peptide were designed to produce an amplicon of approximately 100 bp, and the specificity was determined using the National Center for Biotechnology Information Primer-Basic Local Alignment Search Tool. Specific primer sequences are provided in Supplemental Table S1 . The qPCR reaction conditions were as follows: initial denaturation for 2 min at 94°C, followed by 40 cycles of denaturation (94°C, 15 s), annealing, and extension (60°C, 1 min). Relative expression of the gene of interest was analyzed using the DDCq calculation method. b-Actin and glyceraldehyde phosphate dehydrogenase (GAPDH) were used to normalize qPCR results for mice and humans, respectively. b-Actin was used as the reference gene to normalize the gene expression data for the animal studies because no variation in b-actin expression was observed across different genotypes or treatment groups. Similarly, no differences in GAPDH levels were observed in the human samples.
Immunoblotting
Protein was extracted from human and mouse LV tissue using icecold modified RIPA buffer. A total of 50 mg of protein was separated using SDS-PAGE and transferred to PVDF membranes, which were probed with anti-VAChT antibody (1:500; Synaptic Systems, Göttingen, Germany) or anti-ChAT antibody (1:500; Abcam, Cambridge, MA, USA). a-Actinin (1:2000; Sigma-Aldrich) was used as a loading control.
Immunostaining
Murine adult cardiomyocytes and atrial tissues were subjected to an immunostaining protocol as previously described (30) . Cells were costained with anti-ChAT (1:100; Abcam) and anti-a-actinin (1:200; Sigma-Aldrich) antibodies. a-Actinin-labeled cells were used to measure cardiomyocyte cell surface area. Atrial tissue was stained with anti-VAChT (1:200; Synaptic Systems). Hoechst 33342 (Life Technologies, Gibco, Carlsbad, CA, USA) was used as the nuclear marker. Images were acquired using the Zeiss LSM 510 Meta confocal system (Carl Zeiss GmbH, Jena, Germany).
For human LV tissue, 5 mm sections were subjected to the immunofluorescence protocol as previously described (30) . The tissue was incubated with either anti-VAChT (1:100; Synaptic Systems) or anti-ChAT (1:100; Abcam) and anti-a-actinin (1:500; Sigma-Aldrich). Images were acquired using the 363 objective on the Zeiss LSM 510 Meta confocal system.
All imaging parameters, including laser power (Ar: 5%; HeNe 1 and HeNe 2 : 10%) and pinhole size (1 airy unit), as well as PMT gain and offset, remained constant across all treatment groups imaged within a single experiment. The VAChT antibody utilized for these studies was previously validated in VAChT-KO mice and is known to specifically recognize VAChT in mammalian cardiomyocytes (21) . The ChAT antibody does not recognize the protein in KO animals (Supplemental Fig. S1 ) and therefore is also specific.
Measurement of ACh secretion
Acetylcholine release was measured using the Choline/ACh Quantification Kit (BioVision, Milipitas, CA, USA) or HPLC with electrochemical detection as previously described (21, 31) . Briefly, atrial tissue was isolated from wild-type (WT) and ChAT-ChR2-EYFP mice and incubated in Tyrode solution containing 100 mM pyridostigmine bromide (Sigma-Aldrich; P9797) at 37°C for 2 h. The solution was collected and centrifuged at 10,000 rpm for 5 min at 4°C, and the resulting supernatant was collected and placed on ice. Each sample was assayed in duplicate, and experiments were conducted using at least 3 mice per genotype.
HR and blood pressure measurement
Systolic and diastolic blood pressure as well as HR were recorded from conscious animals using the CODA tail-cuff blood pressure system (Kent Scientific, Torrington, CT, USA) as previously described (21, 32) .
Electrocardiography
Radiofrequency telemeters were implanted in WT and ChATChR2-EYFP mice subcutaneously, and electrocardiogram recordings were obtained as previously described (21) . HR was recorded continuously over 24 h to obtain baseline recordings. In addition, HR recordings were obtained immediately after intraperitoneal saline injection or after an acute exercise routine, as previously described (21) .
Cardiac sympathovagal balance
After 60 min of basal HR recording, methylatropine (2 mg/kg, i.p.; Sigma-Aldrich) was injected, and the HR was recorded for the next 45 min to assess the effect of vagal blockade on the HR. Propranolol (5 mg/kg, i.p., Sigma-Aldrich) was then injected in the same mouse, and the HR was recorded for an additional 45 min to determine the intrinsic HR). After 24 h, mice were subjected to the same experimental protocol but received autonomic blockers in reverse order (i.e., propranolol followed by methylatropine) in order to calculate the sympathetic effect and the intrinsic HR.
Statistical analysis
Results for all experiments are provided as means 6 SEM. In experiments where the sample size was greater than 3 and the data were normally distributed (as determined using the D'AgostinoPearson omnibus normality test), either a Student's t test or a 1-way ANOVA with a Tukey post hoc test was used to evaluate statistical differences between experimental groups. In experiments where the data were not normally distributed or n = 3, either a MannWhitney test or a Kruskal-Wallis test with the Dunn multiple comparison test was used to determine statistical significance. All statistical analyses were performed by GraphPad Software (La Jolla, CA, USA) or SigmaStat (San Jose, CA, USA). A value of P , 0.05 was considered statistically significant.
Study approval
The use of human HF and control samples was approved by the institutional review board at Duke University Medical Center (Durham, NC, USA). For the animal studies, all animals were maintained and cared for according to an approved animal protocol at the University of Western Ontario (2008-127) and following Canadian Council on Animal Care guidelines.
RESULTS
VAChT levels are increased in failing human myocardium
In order to determine whether the cardiomyocyte NNCS is present in human samples, we used ventricular extracts from control individuals and patients with NICM ( Table 1) and analyzed cholinergic markers. mRNA levels for AChE were not altered in HF individuals compared with nonfailing controls (Fig. 1A) . Similarly, mRNA levels for ChAT were slightly but not significantly (P = 0.1511) increased in human HF samples compared with age-matched healthy controls (Fig. 1B) . Immunoblot and immunofluorescence analysis confirmed that ChAT protein levels were not altered in HF (Fig. 1C, D) and showed the presence of ChAT immunoreactivity in cardiomyocytes (Fig. 1D, arrows) . The specificity of the ChAT antibody was demonstrated by the lack of protein detection in samples from conditional ChAT-KO mice.
In contrast to lack of changes in ChAT and AChE levels, VAChT mRNA levels were significantly increased in HF patients compared with age-matched controls (Fig. 1E ). Immunoblot and immunofluorescence analyses indicated that VAChT protein levels were also increased in HF patients compared with controls (Fig. 1F, G) . Furthermore, examination of sections costained with VAChT and a-actinin suggests that the increased levels of VAChT at least in part originated in cardiomyocytes (Fig. 1G, arrows) .
cVAChT mice exhibit increased Ang II-mediated cardiac dysfunction and remodeling
In order to clarify whether changes in the expression levels of VAChT and consequently ACh secretion could affect pathologic remodeling, we used cVAChT mice, which have decreased secretion of ACh. We treated cVAChT mice chronically with Ang II or saline. Ang II is a potent vasoconstrictor that activates AT 1 receptors on vascular smooth muscle cells (33, 34) and can thereby induce ventricular remodeling (35) . Furthermore, Ang II-mediated signaling has also been shown to directly induce hypertrophy and molecular remodeling in ventricular cardiomyocytes (36) (37) (38) . We chose a pharmacologic treatment instead of surgical induction of HF in mice in an attempt to produce moderate cardiac dysfunction, in the event that the lack of nonneuronal cholinergic signaling led to worse outcomes.
Ang II treatment in cVAChT mice led to a significantly greater decrease in LV fractional shortening and ejection fraction compared with control animals, as assessed through noninvasive analysis of LV hemodynamics using M-mode echocardiography ( Fig. 2A-C) . We observed no LV dilation after Ang II treatment in cVAChT mice, and LV internal dimensions were similar to control mice both in diastole and systole (Fig. 2D) .
In order to determine pathologic hallmarks in cVAChT mice that may contribute to the worsened LV function observed after Ang II, heart weight and cardiomyocyte surface area were analyzed. VAChT flox/flox control mice displayed an increase in heart weight after Ang II treatment compared with saline-treated mice (Fig. 3A) . Conversely, cVAChT mice displayed baseline cardiac hypertrophy with saline treatment alone, as we previously described (21); however, compared with saline-treated animals, Ang II treatment did not induce further significant increase in heart weight in cVAChT mice (Fig. 3A) . However, an analysis of cardiomyocyte surface area in situ revealed that Ang II-treated cVAChT mice exhibited a significantly greater cardiomyocyte hypertrophic response than Ang II-treated control mice (Fig. 3B) .
Chronic Ang II exposure can lead to increased reactive oxygen species production and cardiomyocyte death (39) (40) (41) . We observed that under baseline conditions with saline treatment there was an increase in oxidative stress in the hearts of cVAChT mice compared with control mice (Fig. 3C) . Furthermore, Ang II treatment led to a greater increase in oxidative stress in the myocardium in cVAChT mice compared with Ang II-treated control mice (Fig. 3C) .
In addition to the changes in oxidative stress, Ang IItreated cVAChT mice displayed a greater disruption of myocardial structure compared with VAChT flox/flox control mice (Fig. 3D ). An increase in fibrotic response was observed after treatment with Ang II in VAChT flox/flox and cVAChT mice; however, in cVAChT mice, more prominent fibrosis due to increased interstitial and perivascular collagen deposition was observed (Fig. 3E) .
cChAT mice display altered HR regulation and cardiac remodeling
VAChT is part of the major facilitator superfamily of transporters, which includes members of the multidrug Figure 1 . Human cardiomyocytes express markers of cholinergic system. A) mRNA levels for AChE are unaltered in NICM. B,C) No difference in ChAT mRNA (B) or protein level (C ) is observed in NICM. D) Perinuclear staining for ChAT is observed in cardiomyocytes from both nonfailing and NICM samples. E, F) VAChT mRNA (E ) and protein (F ) levels are increased in NICM. G) Punctate VAChT staining is observed in perinuclear region of cardiomyocytes and increased in NICM samples. mRNA levels were analyzed by qPCR; data are presented as means 6 SEM. n $ 4 subjects for all experiments. Scale bar = 25 mm. Student's t test was used to determine statistical differences. *P , 0.05. resistance protein family, and has been shown to transport other organic substrates, including choline (42, 43) . To provide causal relationship for a role of secreted ACh, we used mice in which cardiomyocyte-specific ACh synthesis was selectively eliminated (cChAT mice).
cChAT mice, which lack expression of ChAT in cardiomyocytes (Supplemental Fig. S1A, B) , did not display changes in baseline HR (Supplemental Fig. S1C ) compared with littermate controls. However, they exhibited delayed HR recovery after handling stress using an intraperitoneal injection of saline (Supplemental Fig. S1D ) or after acute low-intensity treadmill exercise test (Supplemental Fig.  S1E ). In addition, cChAT cardiomyocytes displayed hypertrophy and molecular remodeling (Supplemental Fig. S2 ). These results are essentially the same as we previously reported for cVAChT mice (21) , suggesting that elimination of either ACh synthesis or its secretion from cardiomyocytes causes similar cardiovascular phenotypes.
cChAT mice exhibit enhanced Ang II-mediated cardiac dysfunction and remodeling Similar to cVAChT mice, Ang II treatment led to a significant decrease in LV fractional shortening and LV ejection fraction in both control and cChAT mice (Supplemental Fig. S1A-C) . Interestingly, cardiac function in cChAT mice was impaired under baseline conditions. Furthermore, cChAT mice exhibited a significantly greater decrease in both LV fractional shortening and ejection fraction compared with Ang II-treated control mice (Supplemental Fig. S3B, C) , thus suggesting that cChAT mice were more sensitive to Ang II-mediated cardiac dysfunction. In contrast to the experiments using cVAChT mice, Ang IItreatment led to LV dilation in cChAT, but not control mice (ChAT flox/flox ; Supplemental Fig. S3D ). These results suggest that cChAT mice may have a slightly stronger phenotype than cVAChT mice, especially considering the fact that cChAT mice show basal cardiac dysfunction, which is not as apparent in cVAChT mice.
In contrast to Ang II-treated cChAT and cVAChT mice, a separate set of control experiments revealed that Myh6-Cre + mice displayed ventricular dysfunction similar to WT littermates after Ang II treatment (Supplemental Fig. S4 ). However, distinct from control mice, Myh6-Cre + mice displayed enhanced ventricular dilation during systole after Ang II treatment compared with saline-treated mice (Supplemental Fig. S4D ).
To further examine whether the enhanced molecular remodeling observed in cVAChT mice was due to impaired secretion of cardiac nonneuronal acetylcholine, pathologic remodeling was also analyzed in saline-and Ang IItreated cChAT mice. ChAT flox/flox mice did not display a significant increase in heart weight after Ang II treatment compared with saline-treated mice (Supplemental Fig.  S5A ). In contrast, cChAT mice displayed a significant increase in heart weight after Ang II treatment compared with saline-treated cChAT animals (Supplemental Fig.  S5A ). Although baseline characterization of cChAT mice revealed cardiac hypertrophy, this phenotype was not observed in saline-treated cChAT mice. The disparity in the observed cardiac hypertrophy might be because mice used in the present Ang II experiment were younger (3 to 4 mo) than those used for baseline measurements (Supplemental Fig. S2 ; 5 to 6 mo). It is possible that the hypertrophic response in cChAT mice is an age-dependent phenotype.
When compared with saline-treated ChAT flox/flox animals, saline-treated cChAT mice displayed cardiomyocyte hypertrophy (Supplemental Fig. S5B ). Furthermore, although both control and cChAT mice displayed a significant increase in cardiomyocyte surface area after Ang II treatment, cChAT mice exhibited significantly greater Kruskal-Wallis test (with Dunn multiple comparison test) was used to determine statistical differences. *P , 0.05, **P , 0.01, ****P , 0.0001. myocyte hypertrophy than ChAT flox/flox control mice (Supplemental Fig. S5B) .
Analysis of oxidative stress in control and cChAT mice after Ang II treatment revealed similar results as those observed in Ang II-treated cVAChT mice. cChAT mice showed an increase in oxidized protein levels compared with ChAT flox/flox controls (Supplemental Fig. S5C ). Ang II treatment in both control and cChAT mice led to an increase in myocardial oxidative stress. Although cChAT mice displayed a tendency for increased levels of oxidative A) Heart weight/tibia length (HW/TL) ratio to assess cardiac hypertrophy. B) Cardiomyocyte hypertrophy after Ang II treatment in both genotypes. C) Analysis of myocardial oxidized protein levels in control and cVAChT mice. D) Qualitative analysis of myocardial structure to determine extent of myocardial disruption and damage. E) Analysis of collagen deposition and fibrosis in VAChT flox/flox and cVAChT hearts. Data are represented as means 6 SEM. n $ 4 mice for all experiments. Scale bar = 60 mm. One-way ANOVA (with Tukey multiple comparison test) was used to determine statistical differences. *P , 0.05, **P , 0.01, ***P , 0.001, ****P , 0.0001. stress compared with control mice, this result did not reach statistical significance (P = 0.0726, Supplemental Fig. S5C ). Hematoxylin and eosin staining revealed that Ang IItreated cChAT mice exhibited a greater disruption of myocardial structure compared with ChAT flox/flox control mice (Supplemental Fig. S5D ). Additionally, trichrome C staining revealed that both ChAT flox/flox and cChAT mice had significantly increased collagen deposition after Ang II treatment; however, the fibrotic response in Ang II-treated cChAT mice was significantly greater than that observed in ChAT flox/flox animals (Supplemental Fig. S5E ). Analysis of pathologic damage and oxidized protein levels in Ang II-treated Myh6-Cre + mice revealed that hearts from mice expressing Cre have similar response as WT controls (Supplemental Fig. S6 ). These results suggest that Cre expression at this age does not contribute to the worse remodeling observed in cChAT or cVAChT mice, suggesting that paracrine/autocrine cholinergic signaling can offset pathology during remodeling.
Increased VAChT expression does not disturb cardiac function
To determine whether increased levels of VAChT observed in human patients would have functional consequences, we utilized mice overexpressing VAChT (ChAT-ChR2-EYFP) for these experiments (44) . This particular line was generated to express channelrhodopsin-2 (ChR2) in cholinergic neurons using a ChAT bacterial artificial chromosome (BAC); however, because the VAChT gene is present in the first intron of the ChAT gene, the transgene caused VAChT overexpression (27) . We first confirmed whether the heart of ChAT-ChR2-EYFP mice overexpressed VAChT. In this line, the ChR2 protein is tagged with EYFP. Immunostaining confirmed the expression of EYFP in cholinergic neurons, which were specifically labeled with the cholinergic marker CHT1 (Fig. 4A) . qPCR analysis revealed that expression of the transgene in the heart led to a significant increase in VAChT mRNA levels (Fig. 4B) . Furthermore, immunostaining confirmed an increase in staining for VAChT, thus suggesting an increase in VAChT protein levels in ChAT-ChR2-EYFP atrial tissue (Fig. 4C) . Notably, VAChT levels were also up-regulated in ventricular cardiomyocytes, suggesting that the BAC transgene is also expressed in cardiomyocytes (Fig. 4D) . In accordance with these data, we also observed increased secretion of ACh from isolated tissue (Fig. 4E, F) .
In order to determine whether this increase in VAChT levels leads to cardiovascular physiologic changes in these mice, we performed tail-cuff analysis to measure blood pressure and HR. No difference in HR or blood pressure was observed between the 2 genotypes using the CODA tail-cuff system, in which mice need to be immobilized (Fig. 5A) . In contrast, the more sensitive electrocardiographic analysis revealed that baseline HR in ChAT-ChR2-EYFP mice over 24 h was significantly lower than control mice (Fig. 5B) , with the main difference in HR being observed during the light cycle (Fig. 5C) . Additionally, administration of a bolus dose of the muscarinic receptor antagonist methylatropine led to a significantly greater increase in the HR of ChAT-ChR2-EYFP mice compared with WT animals (Fig. 5D) . Alternatively, there was no difference in HR response between the 2 genotypes after administration of the b-adrenergic receptor antagonist propranolol (Fig. 5D) . These data suggest that the hearts of ChAT-ChR2-EYFP mice are under greater parasympathetic control than WT animals. In fact, this notion is further supported by the fact that the initial increase in HR after an acute, low-intensity treadmill test is attenuated in ChATChR2-EYFP mice compared with control counterparts (Fig.  5E ), suggesting that response to increased physiologic stress may be offset by the augmented levels of VAChT.
In order to determine whether this increase in cholinergic tone leads to changes in basal LV hemodynamics, we used the Millar catheter technique to assess cardiac function in live animals. Analysis of LV parameters in anesthetized animals was done under both baseline conditions and after the administration of isoproterenol (0.5 mg i.p.). All of the hemodynamic parameters measured using the Millar technique were similar between WT controls and ChAT-ChR2-EYFP mice, both under baseline conditions and after a bolus dose of isoproterenol ( Table 2) . These results suggest that under baseline conditions, increased VAChT expression does not alter LV function.
Ang II-mediated cardiac dysfunction and pathologic remodeling is attenuated in ChAT-ChR2-EYFP mice Similar to the previous experiments with cVAChT and cChAT mice, we chronically treated ChAT-ChR2-EYFP mice with Ang II, which led to a significant decrease in LV fractional shortening and LV ejection fraction in WT control mice (Fig. 6A-C) . Conversely, Ang II-treated ChATChR2-EYFP mice did not display a significant decrease in either LV fractional shortening or ejection fraction (Fig. 6B, C) .
Analysis of pathologic remodeling after Ang II treatment revealed that WT mice display both cardiac and cardiomyocyte hypertrophy, whereas ChAT-ChR2-EYFP mice seemed to be protected (Fig. 7A, B) . In addition, ChATChR2-EYFP mice did not show a significant increase in oxidative stress after Ang II treatment, which could be easily detected in WT mice (Fig. 7C) . In addition to attenuated oxidative stress, qualitative analysis of the myocardium revealed that disruption of myocardial structure was reduced in Ang II-treated ChAT-ChR2-EYFP mice compared with WT animals (Fig. 7D) . Finally, the fibrotic response after Ang II treatment was only observed in WT, but not ChAT-ChR2-EYFP, mice (Fig. 7E) .
DISCUSSION
The role of parasympathetic signaling in heart disease is still not fully understood, but autonomic imbalance with reduced parasympathetic activity has been described (8-10). Here we provide evidence that in HF VAChT levels are increased in the ventricles and specifically in cardiomyocytes. This observation is in line with previous work that revealed a transdifferentiation-induced increase in the expression of cholinergic markers in HF (12) . Furthermore, it was previously shown that the expression of cholinergic markers in ventricular myocytes is related to myocardial ACh availability. Increasing ACh levels using pyridostigmine led to a significant down-regulation of nonneuronal cholinergic machinery in cardiomyocytes (18) . Conversely, the expression of ChAT and VAChT in ventricular myocytes was up-regulated after treatment with the sympathetic agonist isoproterenol. Together, these observations suggest that in response to decreased vagal activity there are multiple compensatory increases in cholinergic markers in HF.
To our knowledge, this is the first report to reveal the existence of a NNCS in human cardiomyocytes and to report augmented VAChT expression in HF. This increase in VAChT levels in human patients with NICM and HF hints at the possibility that ventricular myocytes may be able to increase cardiac ACh secretion as a compensation for decreased vagal activity.
We used mice that reproduced the increase in VAChT levels (ChAT-ChR2-EYFP) and determined that increased cholinergic signaling did not lead to adverse effects in the cardiovascular system. In fact, our experiments revealed that although the increase in ACh release does not alter basal LV contractility in these mice, the hearts of ChATChR2-EYFP mice are under greater parasympathetic control and also display an attenuated increase in exerciseinduced HR. These data suggest that under physiologic conditions, enhancing cholinergic signaling plays a role in regulating chronotropic, but not inotropic, responses. The blunted response to activity further suggests that increased ACh signaling in the heart may lead to greater control of the heart under conditions of increased sympathetic drive, as seen in disease states.
The enhanced cholinergic signaling in ChAT-ChR2-EYFP mice also mitigated Ang II-mediated ventricular remodeling. These genetically modified mice did not develop LV dysfunction and pathologic remodeling to the same extent as WT mice after challenge with Ang II. This observation is in line with previous work suggesting that increasing ACh levels yields positive results in HF (12) (13) (14) (15) (16) (17) (18) . The fact that an increase in systemic ACh secretion in mice partially offsets the deleterious effects of Ang II suggests that the increase in VAChT levels seen in failing human myocardium may help to delay progression of HF in humans.
Given that ChAT-ChR2-EYFP mice overexpress VAChT in both cardiac parasympathetic neurons and ventricular cardiomyocytes, there is a possibility that some of the positive effects observed in these transgenic mice after Ang II treatment are due to increased activity of the cardiac NNCS. In order to test this possibility, we used mice lacking either the ability to produce (cChAT mice) or release (cVAChT mice) ACh. Our results revealed that the NNCS plays a key role in regulating the extent of cardiac disease. Chronic treatment with Ang II in cChAT and cVAChT mice led to enhanced cardiac remodeling characterized by increased oxidative stress and myocyte hypertrophy. It is likely that the heightened disruption of myocardial structure and increased fibrotic response in KO mice contributes to the observed LV dysfunction and decreased ventricular compliance. These data suggest that the NNCS normally plays a critical role in attenuating the ventricular remodeling response.
It is possible that the increased oxidative stress observed in cChAT and cVAChT mice leads to cardiomyocyte death, which may serve as a precursor for the accelerated ventricular remodeling and dysfunction associated with chronic Ang II infusion. The molecular mechanisms that regulate this enhanced remodeling response by secreted ACh have yet to be fully elucidated. Long-term cholinergic signaling via muscarinic receptors may regulate the expression of key components of cardiomyocyte stressrelated proteins (45) (46) (47) . Alternatively, the NNCS may Figure 5 . Parasympathetic regulation of cardiac function in ChAT-ChR2-EYFP mice. A) Systolic and diastolic blood pressure and HR using CODA tail-cuff system in WT and ChAT-ChR2-EYFP mice. B) HR over 24 h in awake, free-moving WT and ChAT-ChR2-EYFP mice in their home cage. C ) Comparison of mean HR during light and dark cycles between 2 genotypes. D) HR response to acute bolus dose of atropine or propranolol in WT and ChAT-ChR2-EYFP mice. E ) HR response to short burst of exercise in WT controls and ChAT-ChR2-EYFP mice. n $ 7 mice for all experiments. Data are represented as means 6 SEM. Statistical differences were analyzed by either Student's t test (A, C, D) or 2-way ANOVA (with Sidak multiple comparison test) (B, E ). *P , 0.05. regulate cardiomyocyte function in a non-cell-autonomous way by regulating local inflammatory responses. It is well established that cholinergic activity controls innate inflammatory responses by secretion of ACh from a subpopulation of T cells, the so-called cholinergic antiinflammatory pathway (48) (49) (50) . Whether secretion of ACh from cardiomyocytes may regulate local inflammatory cells in the heart remains to be determined. It is noteworthy, however, that inflammation contributes to cardiac remodeling and dysfunction in HF (51) (52) (53) (54) (55) (56) .
In agreement with the current study, previous work from other groups has also demonstrated the importance of the NNCS. Cardiomyocyte-specific overexpression of the enzyme choline acetyltransferase (ChAT-Tg) attenuates ventricular remodeling and increases survival after myocardial infarction by mechanisms regulating cellular stress (24) . ChAT-KO HL-1 cells, derived from murine atrial cardiac tissue, exhibit decreased viability in response to chemical hypoxia (57) . These studies further implicate the cardiac NNCS in the regulation of cardiac function, especially after induction of stress, including ischemia.
It remains to be determined whether vagal stimulation can also increase activity of the NNCS. Vagal stimulation is known to increase overall cholinergic signaling in the heart and improve cardiovascular parameters in experimental HF (13, 14) , an effect that can be mimicked by using cholinesterase inhibitors (15) (16) (17) . Although the mechanisms through which treatment with cholinesterase inhibitors can induce protective effects have yet to be explored, a nationwide cohort study from Sweden revealed that the use of cholinesterase inhibitors in Alzheimer disease patients leads to a 34% reduction in risk of myocardial infarction and death (20) . It is possible that at least some of the positive effects observed in response to increased cholinergic activity using cholinesterase inhibitors are due to enhanced signaling of the cardiac NNCS.
We propose that the increase in VAChT levels in HF may not be deleterious but rather may help to offset cardiac remodeling. Obviously, this increase in VAChT expression does not completely prevent remodeling in endstage disease, but experiments in mice suggest that ventricular remodeling in HF would be worse in the absence of this compensatory mechanism. Our data indicate Figure 6 . Cardiac dysfunction in WT and ChAT-ChR2-EYFP mice after Ang II treatment. A) Representative images of M-mode echocardiography. B, C) LV fractional shortening (B) and ejection fraction (C) in Ang II-treated mice. D) LV internal dimensions during diastole and systole were analyzed to determine extent of ventricular dilation in both control and ChAT-ChR2-EYFP mice. Data are represented as means 6 SEM. n $ 6 mice for all experiments. Kruskal-Wallis test (with Dunn multiple comparison test) was used to determine statistical differences, *P , 0.05. that cardiomyocyte-secreted ACh plays a critical role in regulating the onset and progression of LV dysfunction in mice. Up-regulation of markers of the cholinergic system may partially restore cholinergic signaling to baseline levels after vagal withdrawal. In addition, increased cholinergic signaling may counteract the effects of the increased sympathetic drive observed in heart disease. Our results support the notion that increased cholinergic signaling, such as that achieved by cholinesterase inhibitors, may lead to positive outcomes in HF patients. Cholinesterase inhibitors are well characterized as a treatment option in patients with Alzheimer disease; therefore, modulation of both neuronal parasympathetic signaling and NNCS through the use of cholinesterase inhibitors may serve as an unexplored clinical avenue for the treatment of cardiac disease in humans. Figure 7 . Ang II-mediated ventricular hypertrophy and remodeling in WT and ChAT-ChR2-EYFP mice. A) Heart weight/tibia length (HW/TL) ratio in saline and Ang II-treated WT and ChAT-ChR2-EYFP mice. B) Cardiomyocyte cell surface area in WT and ChAT-ChR2-EYFP mice. C ) Levels of myocardial oxidized protein after Ang II treatment in both genotypes. D) Qualitative analysis of myocardial structure and disruption in both genotypes. E ) Collagen deposition in WT and ChAT-ChR2-EYFP mice. Data are represented as means 6 SEM. n $ 4 mice for all experiments. Scale bar = 60 mm. One-way ANOVA (with Tukey multiple comparison test) was used to determine statistical differences. *P , 0.05, **P , 0.01, ***P , 0.001.
